![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Diabetic Gastroparesis Candidate Fails in Phase 3
Diabetic Gastroparesis Candidate Fails in Phase 3
July 26, 2016
Evoke Pharma’s drug candidate EVK-001 sunk in a Phase 3 trial assessing its use in female patients with symptomatic diabetic gastroparesis.
The candidate failed to meet its primary endpoint of symptom improvement at week four, the California-based company said.
The company said that data from multiple clinical sites revealed patient improvement, but this was not consistent among all study locations.
Upcoming Events
-
21Oct